Ligand Pharmaceuticals, Inc.

Escient Pharmaceuticals, Inc.

Receptos, Inc.

Celgene International Ii Sarl

Conforma Therapeutics Corporation

The Salk Institute for Biological Studies

Baylor College of Medicine

Other

Eli Lilly and Company

Eisai Inc.

Marcus F Boehm

Esther Martinborough

Liming Huang

Adam Richard Yeager

Manisha Moorjani

Junko Tamiya

Enugurthi Brahmachary

Richard Alan Heyman

Premji Meghani

Andrew Richard Novak

Thomas Fowler

Marcos Sainz

Brandon Selfridge

Michael Knaggs

Marion Lanier

Srinivas Rao Kasibhatla

Lin Zhang

Ronald Mark Evans

David John Mangelsdorf

Alex M Nadzan

Marco Antonio Biamonte

Gregor Eichele

Christina Thaller

Kevin Hong

Jiandong Shi

Lin Zhi

Robert Peach

Michael Allen Hanson

Jennifer L Brooks

Fiona Lorraine Scott

Gregg Alan Timony

Jean-Yves Le Brazidec

Pierre-Yves Michellys

Chan Kou Hwang

Youssef L Bennani

Mark T Griffith

Junhua Fan

Christopher M Mapes

Daniel Glynn

Mark Mills

Steve White

Sean Konrad McHugh

Todd Kevin Jones

Lawrence G Hamann

Luc J Farmer

Robert J Ardecky

Timothy A Grese

David Andrew Neel

John S Tyhonas

Lawrence C Fritz

Kevin Matthew Gardinier

Siead Zegar

Ranjan Mukherjee

Douglas Linn Gernert

Jyun-Hung Chen

Beth Ann Badea

Elizabeth A Allegretto

Anthony W Thompson

Laura J Dardashti

Margaret A Harmon

Francis J Burrows

David Hurst

Stacie Canan Koch

Chan Kou (Jack) Hwang

Amy L Faulkner

Stacie Canan-Koch

Deepak S Lala

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q, Q, Z, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X4 and related products and methods

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X4 and related products and methods

Modulators of mas-related G-protein receptor X4 and related products and methods

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where '' represents either or both the R and S form of the compound): where A, B, C, Y, Y, Z, R, R, R, R, R, W, n, p and q are as defined herein.

GLP-1 receptor modulators

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Growing community of inventors

San Diego, CA, United States of America

Marcus F Boehm